



NDA 203858/S-010

SUPPLEMENT APPROVAL

Aegerion Pharmaceuticals, Inc.
Attention: Martha J. Carter
Chief Regulatory Officer and Senior Vice President
One Main Street, Suite 800
Cambridge, MA 02142

Dear Ms. Carter:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 4, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Juxtapid (lomitapide) capsules, 5, 10, and 20 mg.

We acknowledge receipt of your amendments dated November 7, December 4, 2014, and January 15, and February 4, 2015.

The January 15, 2015, submission constituted a complete response to our December 23, 2014, action letter.

This "Prior Approval" supplemental new drug application provides for the addition of 30, 40, and 60 mg strength capsules and associated labeling revisions.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the Medication Guide, carton and container labeling), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your September 4, 2014, submission containing final printed carton and container labels.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Senior Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

James P. Smith, MD, MS
Deputy Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling (Package Insert, Medication Guide)
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JAMES P SMITH
04/23/2015